Islet Pathology and the Pathogenesis of Type 1 and Type 2 Diabetes mellitus Revisited
The DOI matches its Crossref record.
Abstract
The present review draws attention to the diversity of islet lesions seen in human type 1 and type 2 diabetes. This heterogeneity of islet changes is best demonstrated by immunocytochemistry. In type 1 diabetes the endocrine pancreas is characterized by selective loss of B cells, which most likely results from a slowly acting autoimmune process depending on the presence of both genetic and environmental factors. The process starts years before overt diabetes develops and manifests when the B-cell volume is reduced by about 80%. In type 2 diabetes B cells are always present, regardless of the duration and severity of the disease, but lack any signs of functional activity. This reflects a secretory defect of the B cells which obviously becomes evident under the conditions of obesity, hyperinsulinism and insulin resistance. Obese but non-diabetic subjects show, in parallel to their hyperinsulinism, an increased B cell volume, suggesting that under prediabetic conditions the B cells have still the capacity to respond to increased functional demands by enhanced proliferation. In manifest diabetes the B cells have lost their proliferative potential. Whether this is due to an inherent defect or the consequence of a functional disturbance, is not clear. The development of islet amyloidosis most likely represents an associated functional abnormality of the B cell.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Mechanisms linking obesity to insulin resistance and type 2 diabetes
Kahn, S. E., Hull, R. L., & Utzschneider, K. M. (2006) · Nature · doi:10.1038/nature05482 · Cited by 5,448
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis
Hales, C. N., & Barker, D. J. P. (1992) · Diabetologia · doi:10.1007/bf00400248 · Cited by 3,309
Fetal and infant growth and impaired glucose tolerance at age 64
Hales, C. N., Barker, D. J., Clark, P. M., Cox, L. J., Fall, C., Osmond, C., & Winter, P. D. (1991) · BMJ · doi:10.1136/bmj.303.6809.1019 · Cited by 2,708
Disruption of IRS-2 causes type 2 diabetes in mice
Withers, D. J., Gutierrez, J. S., Towery, H., Burks, D. J., Ren, J.-M., Previs, S., Zhang, Y., Bernal, D., Pons, S., Shulman, G. I., et al. (1998) · Nature · doi:10.1038/36116 · Cited by 1,775
Epidemic obesity and type 2 diabetes in Asia
Yoon, K.-H., Lee, J.-H., Kim, J.-W., Cho, J. H., Choi, Y.-H., Ko, S.-H., Zimmet, P., & Son, H.-Y. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69703-1 · Cited by 1,580
Mechanisms of Pancreatic β-Cell Death in Type 1 and Type 2 Diabetes
Cnop, M., Welsh, N., Jonas, J.-C., Jörns, A., Lenzen, S., & Eizirik, D. L. (2005) · Diabetes · doi:10.2337/diabetes.54.suppl_2.s97 · Cited by 1,491
Pathogenesis of type 2 diabetes mellitus
DeFronzo, R. A. (2004) · Medical Clinics of North America · doi:10.1016/j.mcna.2004.04.013 · Cited by 1,342
Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
The Role for Endoplasmic Reticulum Stress in Diabetes Mellitus
Eizirik, D. L., Cardozo, A. K., & Cnop, M. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0015 · Cited by 1,173
Five stages of evolving beta-cell dysfunction during progression to diabetes
Weir, G. C., & Bonner-Weir, S. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s16 · Cited by 1,126
Pancreatic β‐cell mass in European subjects with type 2 diabetes
Rahier, J., Guiot, Y., Goebbels, R. M., Sempoux, C., & Henquin, J. C. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00969.x · Cited by 756
Regulation of Insulin Synthesis and Secretion and Pancreatic Beta-Cell Dysfunction in Diabetes
Fu, Z., R. Gilbert, E., & Liu, D. (2013) · Current Diabetes Reviews · doi:10.2174/157339913804143225 · Cited by 732
β-Cell Failure in Diabetes and Preservation by Clinical Treatment
Wajchenberg, B. L. (2007) · Endocrine Reviews · doi:10.1210/10.1210/er.2006-0038 · Cited by 714
Polymicrobial Interactions: Impact on Pathogenesis and Human Disease
Peters, B. M., Jabra-Rizk, M. A., O'May, G. A., Costerton, J. W., & Shirtliff, M. E. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.00013-11 · Cited by 712
Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis
Hales, C., & Barker, D. (2013) · International Journal of Epidemiology · doi:10.1093/ije/dyt133 · Cited by 708
Meier, J. J., Butler, A. E., Saisho, Y., Monchamp, T., Galasso, R., Bhushan, A., Rizza, R. A., & Butler, P. C. (2008) · Diabetes · doi:10.2337/db07-1369 · Cited by 683
“-Cell mass can be adaptively increased in humans, for example, in obesity (8,15), but the extent of this adaptive increase is modest compared with that in obese rodents ( 0.”
ResultSakuraba, H., Mizukami, H., Yagihashi, N., Wada, R., Hanyu, C., & Yagihashi, S. (2002) · Diabetologia · doi:10.1007/s125-002-8248-z · Cited by 681
The Importance of β-Cell Failure in the Development and Progression of Type 2 Diabetes
Kahn, S. E. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.9.7713 · Cited by 660
Selective β-Cell Loss and α-Cell Expansion in Patients with Type 2 Diabetes Mellitus in Korea
Yoon, K. H., Ko, S. H., Cho, J. H., Lee, J. M., Ahn, Y. B., Song, K. H., Yoo, S. J., Kang, M. I., Cha, B. Y., Lee, K. W., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020735 · Cited by 649
Islet Amyloid in Type 2 Diabetes, and the Toxic Oligomer Hypothesis
Haataja, L., Gurlo, T., Huang, C. J., & Butler, P. C. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0037 · Cited by 612
Initiation and execution of lipotoxic ER stress in pancreatic β-cells
Cunha, D. A., Hekerman, P., Ladrière, L., Bazarra-Castro, A., Ortis, F., Wakeham, M. C., Moore, F., Rasschaert, J., Cardozo, A. K., Bellomo, E., et al. (2008) · Journal of Cell Science · doi:10.1242/jcs.026062 · Cited by 594
Saturated Fatty Acids Synergize with Elevated Glucose to Cause Pancreatic β-Cell Death
El-Assaad, W., Buteau, J., Peyot, M.-L., Nolan, C., Roduit, R., Hardy, S., Joly, E., Dbaibo, G., Rosenberg, L., & Prentki, M. (2003) · Endocrinology · doi:10.1210/en.2003-0410 · Cited by 587
The Influence of GLP-1 on Glucose-Stimulated Insulin Secretion
Kjems, L. L., Holst, J. J., Vølund, A., & Madsbad, S. (2003) · Diabetes · doi:10.2337/diabetes.52.2.380 · Cited by 582
“Mean plasma GLP-1 (7-36) amide concentrations during saline (Œ) or intravenous infusion of GLP-1 (7-36 amide) at a dose of 0.”
BackgroundMethodInfluentialPick, A., Clark, J., Kubstrup, C., Levisetti, M., Pugh, W., Bonner-Weir, S., & Polonsky, K. S. (1998) · Diabetes · doi:10.2337/diabetes.47.3.358 · Cited by 551
Distinct Effects of Saturated and Monounsaturated Fatty Acids on β-Cell Turnover and Function
Maedler, K., Spinas, G. A., Dyntar, D., Moritz, W., Kaiser, N., & Donath, M. Y. (2001) · Diabetes · doi:10.2337/diabetes.50.1.69 · Cited by 552
Obesity and Type 2 Diabetes: What Can Be Unified and What Needs to Be Individualized?
Eckel, R. H., Kahn, S. E., Ferrannini, E., Goldfine, A. B., Nathan, D. M., Schwartz, M. W., Smith, R. J., & Smith, S. R. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0585 · Cited by 552
Gunton, J. E., Kulkarni, R. N., Yim, S., Okada, T., Hawthorne, W. J., Tseng, Y.-H., Roberson, R. S., Ricordi, C., O’Connell, P. J., Gonzalez, F. J., et al. (2005) · Cell · doi:10.1016/j.cell.2005.05.027 · Cited by 492
Chen, C., Cohrs, C. M., Stertmann, J., Bozsak, R., & Speier, S. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.06.019 · Cited by 489
Saisho, Y., Butler, A. E., Meier, J. J., Monchamp, T., Allen‐Auerbach, M., Rizza, R. A., & Butler, P. C. (2007) · Clinical Anatomy · doi:10.1002/ca.20543 · Cited by 479
Butler, A. E., Campbell-Thompson, M., Gurlo, T., Dawson, D. W., Atkinson, M., & Butler, P. C. (2013) · Diabetes · doi:10.2337/db12-1686 · Cited by 457
Unique Arrangement of α- and β-Cells in Human Islets of Langerhans
Bosco, D., Armanet, M., Morel, P., Niclauss, N., Sgroi, A., Muller, Y. D., Giovannoni, L., Parnaud, G., & Berney, T. (2010) · Diabetes · doi:10.2337/db09-1177 · Cited by 450
Inada, A., Nienaber, C., Katsuta, H., Fujitani, Y., Levine, J., Morita, R., Sharma, A., & Bonner-Weir, S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805803105 · Cited by 448
Decreased beta-cell mass in diabetes: significance, mechanisms and therapeutic implications
Donath, M. Y., & Halban, P. A. (2004) · Diabetologia · doi:10.1007/s00125-004-1336-4 · Cited by 430
Inflammatory mediators and islet ?-cell failure: a link between type 1 and type 2 diabetes
Donath, M. Y., St�rling, J., Maedler, K., & Mandrup-Poulsen, T. (2003) · Journal of Molecular Medicine · doi:10.1007/s00109-003-0450-y · Cited by 422
Huang, C.-J., Lin, C.-Y., Haataja, L., Gurlo, T., Butler, A. E., Rizza, R. A., & Butler, P. C. (2007) · Diabetes · doi:10.2337/db07-0197 · Cited by 416
Regulation of pancreatic beta-cell mass
Bouwens, L., & Rooman, I. (2005) · Physiological Reviews · doi:10.1152/physrev.00025.2004 · Cited by 411
Butler, A. E., Janson, J., Soeller, W. C., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.9.2304 · Cited by 411
β-Cell Mass and Turnover in Humans
Saisho, Y., Butler, A. E., Manesso, E., Elashoff, D., Rizza, R. A., & Butler, P. C. (2013) · Diabetes Care · doi:10.2337/dc12-0421 · Cited by 402
Intercellular signals regulating pancreas development and function
Kim, S. K., & Hebrok, M. (2001) · Genes & Development · doi:10.1101/gad.859401 · Cited by 402
β-Cell Mass Dynamics in Zucker Diabetic Fatty Rats
Finegood, D. T., McArthur, M. D., Kojwang, D., Thomas, M. J., Topp, B. G., Leonard, T., & Buckingham, R. E. (2001) · Diabetes · doi:10.2337/diabetes.50.5.1021 · Cited by 374
Glucose Induces β-Cell Apoptosis Via Upregulation of the Fas Receptor in Human Islets
Maedler, K., Spinas, G. A., Lehmann, R., Sergeev, P., Weber, M., Fontana, A., Kaiser, N., & Donath, M. Y. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1683 · Cited by 367
Tourrel, C., Bailbé, D., Meile, M.-J., Kergoat, M., & Portha, B. (2001) · Diabetes · doi:10.2337/diabetes.50.7.1562 · Cited by 362
Expansion of β-cell mass in response to pregnancy
Rieck, S., & Kaestner, K. H. (2010) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2009.11.001 · Cited by 358
Pancreatic β-cell identity, glucose sensing and the control of insulin secretion
Rutter, G. A., Pullen, T. J., Hodson, D. J., & Martinez-Sanchez, A. (2015) · Biochemical Journal · doi:10.1042/bj20141384 · Cited by 339
β Cell dysfunction during progression of metabolic syndrome to type 2 diabetes
Hudish, L. I., Reusch, J. E. B., & Sussel, L. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129188 · Cited by 336
Sulfonylurea Induced β-Cell Apoptosis in Cultured Human Islets
Maedler, K., Carr, R. D., Bosco, D., Zuellig, R. A., Berney, T., & Donath, M. Y. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0699 · Cited by 333
High Glucose Causes Apoptosis in Cultured Human Pancreatic Islets of Langerhans
Federici, M., Hribal, M., Perego, L., Ranalli, M., Caradonna, Z., Perego, C., Usellini, L., Nano, R., Bonini, P., Bertuzzi, F., et al. (2001) · Diabetes · doi:10.2337/diabetes.50.6.1290 · Cited by 333
β-cell loss and β-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition
Jurgens, C. A., Toukatly, M. N., Fligner, C. L., Udayasankar, J., Subramanian, S. L., Zraika, S., Aston-Mourney, K., Carr, D. B., Westermark, P., Westermark, G. T., et al. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.02.036 · Cited by 329
A model of β-cell mass, insulin, and glucose kinetics: pathways to diabetes
TOPP, B., PROMISLOW, K., DEVRIES, G., MIURA, R. M., & FINEGOOD, D. T. (2000) · Journal of Theoretical Biology · doi:10.1006/jtbi.2000.2150 · Cited by 330
Effects of dietary glycaemic index on adiposity, glucose homoeostasis, and plasma lipids in animals
Pawlak, D. B., Kushner, J. A., & Ludwig, D. S. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16937-7 · Cited by 325
Islet growth and development in the adult
Bonner-Weir, S. (2000) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0240297 · Cited by 331
Leete, P., Willcox, A., Krogvold, L., Dahl-Jørgensen, K., Foulis, A. K., Richardson, S. J., & Morgan, N. G. (2016) · Diabetes · doi:10.2337/db15-1615 · Cited by 326
The evolution of β‐cell dysfunction and insulin resistance in type 2 diabetes
Bergman, R. N., Finegood, D. T., & Kahn, S. E. (2002) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.32.s3.5.x · Cited by 301
Islet β cell mass in diabetes and how it relates to function, birth, and death
Weir, G. C., & Bonner‐Weir, S. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12031 · Cited by 296
Tourrel, C., Bailbe, D., Lacorne, M., Meile, M.-J., Kergoat, M., & Portha, B. (2002) · Diabetes · doi:10.2337/diabetes.51.5.1443 · Cited by 285
Butler, A. E., Jang, J., Gurlo, T., Carty, M. D., Soeller, W. C., & Butler, P. C. (2004) · Diabetes · doi:10.2337/diabetes.53.6.1509 · Cited by 267
The beta cell lesion in type 2 diabetes: there has to be a primary functional abnormality
Kahn, S. E., Zraika, S., Utzschneider, K. M., & Hull, R. L. (2009) · Diabetologia · doi:10.1007/s00125-009-1321-z · Cited by 260
Kramer, C. K., Zinman, B., & Retnakaran, R. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70006-8 · Cited by 257
Meier, J. J., Butler, A. E., Galasso, R., & Butler, P. C. (2006) · Diabetes Care · doi:10.2337/dc06-0392 · Cited by 249
Gale, J. E., Cox, H. I., Qian, J., Block, G. D., Colwell, C. S., & Matveyenko, A. V. (2011) · Journal of Biological Rhythms · doi:10.1177/0748730411416341 · Cited by 247
“…a consequence of impaired insulin secretion in response to insulin resistance (Bergman et al., 1981) with characteristic islet pathology, including a deficit in beta-cell mass (Butler et al., 2003; Kloppel et al., 1985) and increased beta-cell apoptosis (Huang et al., 2007; Laybutt et al., 2007).”
Backgroundbeta-cell turnover: its assessment and implications.
Bonner-Weir, S. (2001) · Diabetes · doi:10.2337/diabetes.50.2007.s20 · Cited by 230
β-cell failure as a complication of diabetes
Chang-Chen, K. J., Mullur, R., & Bernal-Mizrachi, E. (2008) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-008-9101-5 · Cited by 225
“In contrast, there is a 25– 50% reduction in b-cell mass seen at the time of diagnosis of type 2 diabetes, suggesting that b-cell dysfunction also contributes to the initial disease process [27, 28].”
Montanya, E., Nacher, V, Biarnés, M., & Soler, J. (2000) · Diabetes · doi:10.2337/diabetes.49.8.1341 · Cited by 220
Meier, J. J., & Nauck, M. A. (2010) · Diabetes · doi:10.2337/db09-1899 · Cited by 215
Brereton, M. F., Vergari, E., Zhang, Q., & Clark, A. (2015) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155415583535 · Cited by 206
“11) (Foulis and Stewart 1984; Kloppel et al. 1985; Walker et al. 2011a).”
Relationship Between β-Cell Mass and Fasting Blood Glucose Concentration in Humans
Ritzel, R. A., Butler, A. E., Rizza, R. A., Veldhuis, J. D., & Butler, P. C. (2006) · Diabetes Care · doi:10.2337/diacare.29.03.06.dc05-1538 · Cited by 197
The dynamic plasticity of insulin production in β-cells
Boland, B. B., Rhodes, C. J., & Grimsby, J. S. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.04.010 · Cited by 194
Human IAPP–induced pancreatic β cell toxicity and its regulation by autophagy
Shigihara, N., Fukunaka, A., Hara, A., Komiya, K., Honda, A., Uchida, T., Abe, H., Toyofuku, Y., Tamaki, M., Ogihara, T., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69866 · Cited by 177
“Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance and β cell failure (1); the latter is caused by reduction in β cell function (2, 3) and β cell mass (4–6).”
Gestational diabetes leads to the development of diabetes in adulthood in the rat
Boloker, J., Gertz, S. J., & Simmons, R. A. (2002) · Diabetes · doi:10.2337/diabetes.51.5.1499 · Cited by 170
Intrinsic Regulators of Pancreatic β-Cell Proliferation
Heit, J. J., Karnik, S. K., & Kim, S. K. (2006) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.22.010305.104425 · Cited by 165
Pancreatic β-Cell Proliferation in Obesity
Linnemann, A. K., Baan, M., & Davis, D. B. (2014) · Advances in Nutrition · doi:10.3945/an.113.005488 · Cited by 132
Minireview: Update on Incretin Biology: Focus on Glucagon-Like Peptide-1
Brubaker, P. L. (2010) · Endocrinology · doi:10.1210/en.2010-0115 · Cited by 122
Replication Increases β-Cell Vulnerability to Human Islet Amyloid Polypeptide-Induced Apoptosis
Ritzel, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.7.1701 · Cited by 115
“In obese nondiabetic humans -cell mass increases, presumably in response to insulin resistance induced by obesity (1,3,31).”
BackgroundImpaired islet turnover in human donor pancreata with aging
Reers, C., Erbel, S., Esposito, I., Schmied, B., Büchler, M. W., Nawroth, P. P., & Ritzel, R. A. (2009) · European Journal of Endocrinology · doi:10.1530/eje-08-0596 · Cited by 113
β cells persist in T1D pancreata without evidence of ongoing β-cell turnover or neogenesis
Lam, C. J., Jacobson, D. R., Rankin, M. M., Cox, A. R., & Kushner, J. A. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3806 · Cited by 68
Islets in type 2 diabetes: in honor of Dr. Robert C. Turner
Bonner-Weir, S., & O'Brien, T. D. (2008) · Diabetes · doi:10.2337/db07-1842 · Cited by 66
“However, it was not until 1985 that increased -cell mass in nondiabetic obese people was clearly shown, albeit with a low number of pancreata (13).”
BackgroundInfluentialMatveyenko, A. V., Veldhuis, J. D., & Butler, P. C. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90451.2008 · Cited by 54
Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies
Bonner‐Weir, S., In't Veld, P. A., & Weir, G. C. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12257 · Cited by 54
Breuer, T. G. K., Menge, B. A., Banasch, M., Uhl, W., Tannapfel, A., Schmidt, W. E., Nauck, M. A., & Meier, J. J. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0330 · Cited by 20
Sofra, X., & Badami, S. (2020) · Health · doi:10.4236/health.2020.128076 · Cited by 17
Metadata
- Authors
- Klöppel, G., Löhr, M., Habich, K., Oberholzer, M., & Heitz, P. U.
- Venue
- Pathology and Immunopathology Research
- Publisher
- S. Karger AG
- Published
- 1985
- Volume
- 4
- Issue
- 2
- Pages
- 110-125
- ISSN
- 0253-438X (ISSN-L)
- 0257-2761
- 2235-1655
- OpenAlex
- W2039486174
- Cited by
- 577
- References
- 0
- FWCI
- 43.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.